Cisbio international announced the release of its second IP-One assay, IP-One Elisa, at the 4th Annual GPCR (G-Protein Coupled Receptors) Congress in Barcelona, Spain
This new assay development tool complements Cisbio's existing IP-One HTRF assay to create a portfolio of fundamental assays for IP1 (inositol(1)phosphate) quantification and GPCR screening accessible to all laboratories.
IP-One Elisa is a monoclonal antibody-based assay that can easily detect IP1, one of the major products of the phosphatidyl inositol cascade, which tightly correlates with Gq-coupled activity.
IP-One Elisa reliably and rapidly delivers second messenger measurement and represents a way of precisely investigating molecular events occurring at the membrane level.
This new kit is an adaptation of Cisbio's IP-One HTRF assay, a high throughput screening method based on Cisbio's proprietary HTRF technology and which was launched last year, to the Elisa detection method.
For Cisbio's existing customers that currently deploy HTRF assays, there is a seamless transition to running the IP-One HTRF assay that involves no further capital investment in equipment or technologies.
Cisbio recognized the need to adapt its pioneering IP-One technology into a universal method which larger audiences who are not equipped with an HTRF compatible reader could use as well, and developed IP-One Elisa with academic laboratories in mind.
"Cisbio international continues its commitment to R+D innovation in the field of GPCR screening, and IP-One Elisa is yet another example of this initiative," said Francois Degorce, head of HTRF marketing and business development, Cisbio international.
"It was important for us to enable a larger customer base, whose resources might not allow for investment in compatible laboratory equipment, to also benefit from IP-One technology." The IP-One Elisa kit contains all the components necessary to perform 96 or 480 tests, and is able to measure small levels of IP1 concentration.
Performance wise, IP-One Elisa is rapid, sensitive (EC50: 150nM, detection limit is 10nM), and there is no cross-reactivity with 50uM myo-inositol, PIP2, IP2, IP3, IP4 or PIP3.
Cells are plated in the appropriate cell culture plate and stimulated by a drug of interest; then, after lysis, the supernatant is transferred into the Elisa plate and the IP1 produced is detected by addition of the Elisa reagents.
Over 50 GPCR targets have already been validated with Cisbio's IP-One assays, reconfirming the relevance of IP1 as a new secondary messenger of Gq-protein coupled receptors.
